No abstract is available for this article. DATA AVAILABILITY STATEMENT Data sharing not applicable to this article because no new data were created or analysed. REFERENCES 1, , , , , , et al. Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma. J Eur Acad Dermatol Venereol. 2026. https://doi.org/10.1111/jdv.70692 2, , , , , , et al. Survival outcomes of adjuvant therapy in resected stage III melanoma: results from a real-life cohort study (TAMARIS).
